TD Cowen Maintains Hold on American Express, Lowers Price Target to $335
TD Cowen analyst Moshe Orenbuch maintains American Express (NYSE:AXP) with a Hold and lowers the price target from $338 to $335.
Stocks · News reference
US Stocks Mixed; American Express Shares Fall Following Q2 Results
US stocks mixed, Dow Jones up 0.2%. Real estate shares up 1.3%. American Express falls 6%. Ohmyhome, LiveWire, Vivakor surge. Robin Energy, RADIOPHARM, Codexis down.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Warren Buffett's Berkshire Compounded at 19.7% a Year for 61 Years, a 6,099,294% Cumulative Gain. Can Investors Still Learn From That Playbook Today?
Warren Buffett stepped down as CEO of Berkshire Hathaway after 61 years, during which the stock gained over 6 million percent compared to the S&P 500's 46,000% gain. The article examines whether investors can still benefit from Buffett's investment philosophy of buying well-run businesses at attractive prices and holding them long-term, emphasizing that emotional discipline and selectivity are more important than intelligence in investing.
JPMorgan’s October Stock Picks Hint at 3 ETF Trades: Value, AI Power, Health Care
JPMorgan’s October stock picks spotlight American Express, Liberty Energy and Thermo Fisher, opening ETF plays across value, AI power and health care.
Greg Abel-Led Berkshire Hathaway Owns 26 Dividend Stocks. Here's the One I'd Buy First.
Berkshire Hathaway's portfolio includes 26 dividend-paying stocks out of 29 total holdings. The article recommends Constellation Brands as the top dividend stock to buy, citing its 3.64% yield, cheap valuation at 11x earnings, strong free cash flow growth, and analyst price target suggesting 54% upside potential, despite recent headwinds from demographic shifts and immigration policy impacts.
Codexis Enters Agreement With An Unnamed siRNA Drug Innovator To Explore Stereo-Defined Fragment Synthesis Using Its ECO Synthesis Manufacturing Platform
The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelectSM, a
Piper Sandler Maintains Overweight on Codexis, Lowers Price Target to $8
Piper Sandler analyst Kashy Harrison maintains Codexis (NASDAQ:CDXS) with a Overweight and lowers the price target from $9 to $8.